or Try an Advanced Search...

    ETF Components for XBI - SPDR S&P Biotech ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    NTRA A 0.04 3.30
    INCY C -1.38 3.29
    GILD B 0.33 2.90
    UTHR C 0.13 2.88
    NBIX C 0.76 2.62
    VRTX D -0.90 2.62
    INSM C -1.25 2.43
    ALNY D 0.05 2.38
    ABBV F 1.44 2.33
    AMGN D 0.23 2.28
    SRPT F -0.84 2.28
    BIIB F 0.54 2.19
    MDGL C 1.36 2.17
    EXAS D 1.39 2.05
    VKTX F 1.26 2.00
    BMRN F -0.75 1.98
    REGN F 0.42 1.80
    CYTK D -1.48 1.79
    BPMC C 0.53 1.69
    CRSP D -2.80 1.63
    TGTX B 8.16 1.62
    MRNA F -0.89 1.57
    RVMD B 0.84 1.46
    RNA C -1.12 1.32
    KRYS C -0.83 1.29
    HALO F -1.93 1.27
    EXEL B 0.09 1.23
    ADMA B -0.70 1.23
    ROIV D 2.09 1.18
    ALKS C -1.11 1.13
    IONS F -1.33 1.08
    TWST F 0.73 0.93
    PCVX D 1.55 0.90
    IOVA F 1.35 0.88
    BBIO F 0.69 0.87
    APLS F -1.96 0.86
    GERN C 0.38 0.86
    CRNX B -0.05 0.84
    ACLX C 0.86 0.79
    DYN D -0.10 0.78
    ACAD C -3.20 0.78
    SWTX C -2.71 0.77
    AGIO C -0.86 0.76
    BEAM D -4.06 0.72
    RARE F 0.71 0.69
    RXRX D -5.96 0.66
    PTCT B 1.29 0.64
    FOLD F -1.30 0.63
    IMVT F 0.50 0.62
    RYTM C -1.51 0.61
    NUVL D 1.01 0.60
    NTLA F 6.29 0.58
    PTGX D 4.06 0.58
    VERA C 3.27 0.57
    MIRM B -1.89 0.57
    ARWR D -1.92 0.54
    IDYA F 0.53 0.53
    VCYT B 0.96 0.53
    JANX C -2.55 0.51
    SRRK B -3.68 0.49
    DVAX C 0.29 0.49
    NVAX F 0.31 0.47
    ARDX F 0.91 0.47
    VCEL A 1.24 0.46
    DNLI D -1.35 0.46
    KYMR D -0.99 0.45
    SNDX F -4.26 0.44
    AKRO C 0.38 0.43
    CGON F -1.44 0.42
    ARQT B -0.79 0.42
    BCRX D -0.68 0.42
    CPRX C -1.28 0.41
    KROS D -0.54 0.36
    IRON B 1.15 0.34
    MNKD B -1.31 0.34
    CLDX D 0.95 0.34
    NRIX C 0.22 0.33
    SMMT D -1.53 0.33
    VRDN D 0.58 0.30
    RCKT F -1.38 0.28
    DAWN D -1.84 0.28
    MYGN F 0.29 0.27
    IRWD F -2.84 0.26
    TVTX C 2.91 0.26
    CGEM F -2.74 0.25
    CDNA D -0.54 0.24
    KURA F -38.21 0.24
    XNCR B 0.34 0.24
    APLT B -2.33 0.22
    CDMO A 0.65 0.22
    RCUS F -2.36 0.20
    VIR F -1.41 0.20
    EBS C 2.70 0.20
    REPL C -1.42 0.18
    HUMA F 0.00 0.18
    ALT C 4.72 0.18
    SPRY C -1.55 0.18
    AVXL B 2.89 0.17
    ARCT F 0.93 0.17
    ANNX F 2.71 0.16
    STOK D 1.24 0.16
    ETNB D -0.25 0.16
    MDXG B 0.00 0.16
    COGT D 0.83 0.16
    VERV D -0.77 0.15
    RLAY F -1.72 0.14
    OLMA F -6.76 0.13
    IMNM F -1.07 0.13
    PRTA F -0.63 0.13
    OCGN F 0.26 0.12
    ANAB F 2.41 0.12
    FDMT F -4.64 0.12
    SANA F -6.72 0.12
    RGNX D -2.60 0.12
    ALLO F -1.46 0.11
    CELC F -1.45 0.11
    SAGE F 0.61 0.11
    CCCC F -0.74 0.10
    ERAS C -4.17 0.10
    ORIC F -0.46 0.09
    FATE F -4.95 0.08
    SVRA F 2.64 0.08
    ABUS D 1.45 0.07
    KALV F -0.45 0.07
    SCLX F -0.85 0.06
    YMAB F -0.14 0.06
    ITOS F -1.02 0.06
    ALEC F -0.42 0.04

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Biotechnology Medicine Cancer Life Sciences Clinical Medicine Immunology Organ Systems Biology Disease Immune System Solid Tumors Clinical Development Antibodies Monoclonal Antibody Monoclonal Antibodies Enzymes Infectious Diseases Autoimmune Disease Treatment Of Cancer
    Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Drug Manufacturers - General Medical Devices

    Recent News for SPDR S&P Biotech ETF & its Holdings

    Date Stock Title
    Nov 21 MRNA Major companies that are also popular short-selling stocks
    Nov 21 KURA Kura Oncology Slams The Door On Its Takeover Narrative, And Shares Collapse 26%
    Nov 21 HUMA Humacyte Clinical Results Highlighting Benefit of the ATEV™ in the Repair of Civilian and Military Arterial Injuries Published in JAMA Surgery
    Nov 21 KURA Kura Oncology partners Kyowa Kirin to advance AML treatment
    Nov 21 TGTX TG Therapeutics Ranked Number One Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™
    Nov 21 CRSP CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
    Nov 20 KURA Kura stock slides 17% on Kyowa Kirin deal for ziftomenib
    Nov 20 KURA Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
    Nov 20 FATE Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options
    Nov 20 MYGN Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
    Nov 20 DAWN Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
    Nov 20 AMGN AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
    Nov 20 NRIX Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia
    Nov 20 MRNA CDC warns of an imminent spike in COVID, flu cases
    Nov 20 INSM Insmed: PAH Treatment Advancement With 2nd Half 2025 Top-Line Data
    Nov 20 MDGL Novo semaglutide data in MASH could negatively impact Madrigal's Rezdiffra
    Nov 20 SWTX SpringWorks started at outperform by Evercore ahead of FDA decision
    Nov 20 BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
    Nov 20 VKTX Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
    Nov 20 NVAX Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)
    The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a replication strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.
    Index Fund Stock Market Index Biotechnology S&P Total Market Index ( Biotechnology Segment
    Back to the Main XBI Page...